Tokyo Tape
Sign in
← M3

Half-year report · Q2

2413.TEDINET S100UO9S
Period2024-04-01 → 2024-09-30
Filed2024-11-08
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 47
MetricValuePeriodScopeSource row
Revenue¥124.8bn2024-04-01 → 2024-09-30Cons.Revenue IFRS
Revenue¥238.9bn2023-04-01 → 2024-03-31Cons.Revenue IFRS (5-year summary)
Revenue¥115.8bn2023-04-01 → 2023-09-30Cons.Revenue IFRS
Operating income¥29.0bn2024-04-01 → 2024-09-30Cons.Operating profit loss IFRS
Operating income¥34.6bn2023-04-01 → 2023-09-30Cons.Operating profit loss IFRS
Profit before tax¥29.1bn2024-04-01 → 2024-09-30Cons.Profit loss before tax IFRS
Profit before tax¥68.8bn2023-04-01 → 2024-03-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥37.3bn2023-04-01 → 2023-09-30Cons.Profit loss before tax IFRS
Net income (owners)¥17.3bn2024-04-01 → 2024-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥45.3bn2023-04-01 → 2024-03-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥23.4bn2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income¥19.6bn2024-04-01 → 2024-09-30Cons.Profit loss IFRS
Net income¥25.1bn2023-04-01 → 2023-09-30Cons.Profit loss IFRS
Total assets¥491.5bnat 2024-09-30Cons.Assets IFRS
Total assets¥490.8bnat 2024-03-31Cons.Assets IFRS
Total assets¥461.0bnat 2023-09-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥127.0bnat 2024-09-30Cons.Liabilities IFRS
Total liabilities¥124.1bnat 2024-03-31Cons.Liabilities IFRS
Net assets / equity¥364.4bnat 2024-09-30Cons.Equity IFRS
Net assets / equity¥366.7bnat 2024-03-31Cons.Equity IFRS
Net assets / equity¥345.2bnat 2023-09-30Cons.Equity IFRS
Net assets / equity¥309.5bnat 2023-03-31dCons.Equity IFRS
Equity (owners)¥349.5bnat 2024-09-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥351.9bnat 2024-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥331.6bnat 2023-09-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥148.1bnat 2024-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥149.7bnat 2024-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥135.1bnat 2023-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥118.3bnat 2023-03-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥23.6bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥58.3bn2023-04-01 → 2024-03-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥26.8bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥11.3bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥39.5bn2023-04-01 → 2024-03-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥28.3bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥12.6bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow¥9.4bn2023-04-01 → 2024-03-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow¥15.3bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥25.472024-04-01 → 2024-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥66.682023-04-01 → 2024-03-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥34.472023-04-01 → 2023-09-30Cons.Basic earnings loss per share IFRS
EPS (diluted)¥25.42024-04-01 → 2024-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥66.632023-04-01 → 2024-03-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥34.452023-04-01 → 2023-09-30Cons.Diluted earnings loss per share IFRS
Equity ratio71.1%at 2024-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio71.7%at 2024-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio71.9%at 2023-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 54
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2024-04-01 → 2024-09-30−¥1.9bn
Reconciling Itemsreconcilingrevenue intersegment2024-04-01 → 2024-09-30−¥1.9bn
Reconciling Itemsreconcilingsegment profit2024-04-01 → 2024-09-30−¥1.7bn
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentrevenue2024-04-01 → 2024-09-30¥11.6bn
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentrevenue external2024-04-01 → 2024-09-30¥11.6bn
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥18m
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentsegment profit2024-04-01 → 2024-09-30¥4.1bn
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentrevenue2024-04-01 → 2024-09-30¥11.9bn
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentrevenue external2024-04-01 → 2024-09-30¥11.8bn
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥100m
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentsegment profit2024-04-01 → 2024-09-30¥1.9bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentrevenue2024-04-01 → 2024-09-30¥42.5bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentrevenue external2024-04-01 → 2024-09-30¥40.7bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥1.7bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentsegment profit2024-04-01 → 2024-09-30¥14.6bn
jpcrp040300-q2r_E05425-000Overseasreportable segmentrevenue2024-04-01 → 2024-09-30¥38.0bn
jpcrp040300-q2r_E05425-000Overseasreportable segmentrevenue external2024-04-01 → 2024-09-30¥38.0bn
jpcrp040300-q2r_E05425-000Overseasreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥28m
jpcrp040300-q2r_E05425-000Overseasreportable segmentsegment profit2024-04-01 → 2024-09-30¥6.6bn
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentrevenue2024-04-01 → 2024-09-30¥21.6bn
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentrevenue external2024-04-01 → 2024-09-30¥21.6bn
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥6m
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentsegment profit2024-04-01 → 2024-09-30¥3.0bn
—segment totalrevenue2024-04-01 → 2024-09-30¥125.6bn
—segment totalrevenue external2024-04-01 → 2024-09-30¥123.7bn
—segment totalrevenue intersegment2024-04-01 → 2024-09-30¥1.9bn
—segment totalsegment profit2024-04-01 → 2024-09-30¥30.3bn
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30−¥1.8bn
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-09-30−¥1.8bn
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30¥125m
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentrevenue2023-04-01 → 2023-09-30¥9.0bn
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentrevenue external2023-04-01 → 2023-09-30¥9.0bn
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥21m
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentsegment profit2023-04-01 → 2023-09-30¥3.3bn
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentrevenue2023-04-01 → 2023-09-30¥13.8bn
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentrevenue external2023-04-01 → 2023-09-30¥13.6bn
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥215m
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentsegment profit2023-04-01 → 2023-09-30¥3.6bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentrevenue2023-04-01 → 2023-09-30¥45.5bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentrevenue external2023-04-01 → 2023-09-30¥44.0bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥1.5bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentsegment profit2023-04-01 → 2023-09-30¥18.4bn
jpcrp040300-q2r_E05425-000Overseasreportable segmentrevenue2023-04-01 → 2023-09-30¥32.7bn
jpcrp040300-q2r_E05425-000Overseasreportable segmentrevenue external2023-04-01 → 2023-09-30¥32.6bn
jpcrp040300-q2r_E05425-000Overseasreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥11m
jpcrp040300-q2r_E05425-000Overseasreportable segmentsegment profit2023-04-01 → 2023-09-30¥7.3bn
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentrevenue2023-04-01 → 2023-09-30¥15.3bn
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentrevenue external2023-04-01 → 2023-09-30¥15.3bn
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥7m
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentsegment profit2023-04-01 → 2023-09-30¥1.8bn
—segment totalrevenue2023-04-01 → 2023-09-30¥116.4bn
—segment totalrevenue external2023-04-01 → 2023-09-30¥114.6bn
—segment totalrevenue intersegment2023-04-01 → 2023-09-30¥1.7bn
—segment totalsegment profit2023-04-01 → 2023-09-30¥34.4bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 642
ItemContextValueUnit
Other components of equity IFRSPrior1YearInstant32449000000JPY
Other components of equity IFRSCurrentQuarterInstant26770000000JPY
Retained earnings IFRSPrior1YearInstant263570000000JPY
Retained earnings IFRSCurrentQuarterInstant266599000000JPY
Equity attributable to owners of parent IFRSPrior1YearInstant351915000000JPY
Equity attributable to owners of parent IFRSCurrentQuarterInstant349533000000JPY
Non controlling interests IFRSPrior1YearInstant14786000000JPY
Non controlling interests IFRSCurrentQuarterInstant14917000000JPY
Equity IFRSPrior1YearInstant366701000000JPY
Equity IFRSCurrentQuarterInstant364450000000JPY
Liabilities and equity IFRSPrior1YearInstant490780000000JPY
Liabilities and equity IFRSCurrentQuarterInstant491469000000JPY
Revenue IFRSPrior1YTDDuration115795000000JPY
Revenue IFRSCurrentYTDDuration124819000000JPY
Cost of sales IFRSPrior1YTDDuration46968000000JPY
Cost of sales IFRSCurrentYTDDuration53918000000JPY
Gross profit IFRSPrior1YTDDuration68828000000JPY
Gross profit IFRSCurrentYTDDuration70901000000JPY
Selling general and administrative expenses IFRSPrior1YTDDuration36138000000JPY
Selling general and administrative expenses IFRSCurrentYTDDuration42908000000JPY
Share of profit loss of investments accounted for using equity method IFRSPrior1YTDDuration284000000JPY
Share of profit loss of investments accounted for using equity method IFRSCurrentYTDDuration1308000000JPY
Other income IFRSPrior1YTDDuration1701000000JPY
Other income IFRSCurrentYTDDuration251000000JPY
Other expenses IFRSPrior1YTDDuration116000000JPY
Other expenses IFRSCurrentYTDDuration569000000JPY
Operating profit loss IFRSPrior1YTDDuration34559000000JPY
Operating profit loss IFRSCurrentYTDDuration28982000000JPY
Finance income IFRSPrior1YTDDuration2920000000JPY
Finance income IFRSCurrentYTDDuration1133000000JPY
Finance costs IFRSPrior1YTDDuration157000000JPY
Finance costs IFRSCurrentYTDDuration1041000000JPY
Profit loss before tax IFRSPrior1YTDDuration37322000000JPY
Profit loss before tax IFRSCurrentYTDDuration29074000000JPY
Income tax expense IFRSPrior1YTDDuration12186000000JPY
Income tax expense IFRSCurrentYTDDuration9485000000JPY
Profit loss IFRSPrior1YTDDuration25136000000JPY
Profit loss IFRSCurrentYTDDuration19589000000JPY
Profit loss attributable to owners of parent IFRSPrior1YTDDuration23406000000JPY
Profit loss attributable to owners of parent IFRSCurrentYTDDuration17294000000JPY
Profit loss attributable to non controlling interests IFRSPrior1YTDDuration1730000000JPY
Profit loss attributable to non controlling interests IFRSCurrentYTDDuration2294000000JPY
Profit loss IFRSPrior1YTDDuration25136000000JPY
Profit loss IFRSCurrentYTDDuration19589000000JPY
Basic earnings loss per share IFRSPrior1YTDDuration34.47
Basic earnings loss per share IFRSCurrentYTDDuration25.47
Diluted earnings loss per share IFRSPrior1YTDDuration34.45
Diluted earnings loss per share IFRSCurrentYTDDuration25.40
Profit loss IFRSPrior1YTDDuration25136000000JPY
Profit loss IFRSCurrentYTDDuration19589000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2024-03-31pass
balance sheet identityconsolidated 2024-09-30pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2024-04-01/2024-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2024-04-01/2024-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2024-04-01/2024-09-30pass
statement vs summary · total assetsconsolidated 2024-03-31pass
statement vs summary · total assetsconsolidated 2024-09-30pass